Survey finds 64 percent of UK adults would receive COVID-19 vaccine
A survey of 1,500 adults in the UK showed that most would be happy to receive a COVID-19 vaccine, while nine percent said they would be unlikely to get the vaccine.
List view / Grid view
A survey of 1,500 adults in the UK showed that most would be happy to receive a COVID-19 vaccine, while nine percent said they would be unlikely to get the vaccine.
The European Commission and Moderna have agreed that the company will supply at least 80 million doses of mRNA-1273, the company's COVID-19 vaccine candidate.
The European Commission has fined Teva and Cephalon €60.5 million for a pay-for-delay deal over Cephalon's modafinil and Teva's generic.
The strategy outlines actions to strengthen EU supply chains, encourage innovation and ensure medicines are affordable and sustainable.
The ABPI has commented on the new Spending Review and outlined ways the UK government can help the life sciences sector.
Reports have said that Purdue Pharma has pleaded guilty to three criminal charges over issues regarding its opioid painkiller, OxyContin.
PhRMA and other organisations have challenged action by the HHS and FDA that permits the importation of drugs from Canada without drug manufacturers’ oversight.
According to the BIA, less than four percent of eligible projects received funding from a government programme for early-stage biotech companies.
Report reveals global pharma supply chain leaders are afraid of the vulnerabilities in the end-to-end supply chain as the COVID-19 pandemic continues.
Mary Alice Dwyer and Sameer Lal explain how pharmaceutical companies can embrace a more customer-centric approach through digital transformation.
Reports have found that the COVID-19 pandemic is providing new opportunities for contract and development manufacturing organisations (CDMOs).
Rising at a CAGR of 4.5 percent, the lateral flow assays market is projected increase due to the high prevalence of infectious diseases worldwide.
New principles on diversity in clinical trials in the US have been released to address systemic issues that deter people from participating in studies.
A new analysis suggests that Europe and North America will capture more than 80 percent of the $9.3 billion market by 2030.
This article explores how COVID-19 has impacted clinical investigation sites and what companies could do to mitigate the effect on trials moving forwards.